Background: Atopic dermatitis (AD) is one of the most common skin conditions among infants. Proteins found in cow's milk formula (CMF) have been found to be attributable to heightened AD risk, particularly in infants with familial AD heredity. Previous studies have suggested that intervention with partially hydrolyzed formula in nonexclusively breastfed infants can have a protective effect against AD development. Objective: The aim of the present study was to compare the estimates of the economic impact of reducing the AD incidence by feeding a partially hydrolyzed whey-based formula (PHF-W) instead of a standard CMF to high-risk nonexclusively breastfed urban infants for the first 17 weeks of life in the Philippines, Malaysia, and Singapore. Methods: In each country, a mathematical model simulated AD incidence and burden from birth to 6 years of age of using PHF-W versus CMF in the target population using data from the German Infant Nutritional Intervention study. The models integrated literature, current cost and market data, and expert clinician opinion. Modeled outcomes included AD risk reduction, time spent after AD diagnosis, AD symptom-free days, quality-adjusted life years (QALYs), and costs (direct and indirect). Outcomes were discounted at 3% per year. Costs were expressed in USD. Results: Feeding high-risk infants PHF-W instead of CMF resulted in an estimated absolute 14% (95% CI 1-24) AD risk reduction, a 0.69-year (95% CI 0.25-1.13) reduction in the time spent after AD diagnosis per child, reductions of 16-38 AD days, and gains in 0.02-0.04 QALYs, depending on the country. The per-child AD-related 6-year cost-saving estimates of feeding high-risk infants with PHF-W versus CMF were USD 739 in Singapore, USD 372 in Malaysia, and USD 237 in the Philippines.

1.
Mack Correa MC, Nebus J: Management of patients with atopic dermatitis: the role of emollient therapy. Dermatology Res Pract 2012;2012:836931.
[PubMed]
2.
Spergel JM, Paller AS: Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112:S118-S127.
[PubMed]
3.
Tay YK, Kong KH, Khoo L, Goh CL, Giam YC: The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br J Dermatol 2002;146:101-106.
[PubMed]
4.
Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI: Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009;124:1251-1258.e23.
[PubMed]
5.
Goh DY, Chew FT, Quek SC, Lee BW: Prevalence and severity of asthma, rhinitis, and eczema in Singapore schoolchildren. Arch Dis Child 1996;74:131-135.
[PubMed]
6.
Wang XS, Tan TN, Shek LP, et al: The prevalence of asthma and allergies in Singapore; data from two ISAAC surveys seven years apart. Arch Dis Child 2004;89:423-426.
[PubMed]
7.
Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ: Persistence of mild to moderate atopic dermatitis. JAMA Dermatol 2014;150:593-600.
[PubMed]
8.
Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC: The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005;22:192-199.
[PubMed]
9.
Su JC, Kemp AS, Varigos GA, Nolan TM: Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997;76:159-162.
[PubMed]
10.
Lewis-Jones S: Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006;60:984-992.
[PubMed]
11.
Ho RC, Giam YC, Ng TP, et al: The influence of childhood atopic dermatitis on health of mothers, and its impact on Asian families. Pediatr Allergy Immunol 2010;21:501-507.
[PubMed]
12.
Ngamphaiboon J, Kongnakorn T, Detzel P, Sirisomboonwong K, Wasiak R: Direct medical costs associated with atopic diseases among young children in Thailand. J Med Econ 2012;15:1025-1035.
[PubMed]
13.
Kang KH, Kim KW, Kim DH: Utilization pattern and cost of medical treatment and complementary alternative therapy in children with atopic dermatitis. Pediatr Allergy Respir Dis 2012;22:27-36.
14.
Lee JT, Lam ZC, Lee WT, et al: Familial risk of allergic rhinitis and atopic dermatitis among Chinese families in Singapore. Ann Acad Med Singapore 2004;33:71-74.
[PubMed]
15.
Van Bever HP, Samuel ST, Lee BW: Halting the allergic march. World Allergy Organ J 2008;1:57-62.
[PubMed]
16.
Suh J, Lee H, Lee JH, et al: Natural course of cow's milk allergy in children with atopic dermatitis. J Korean Med Sci 2011;26:1152-1158.
[PubMed]
17.
Novembre E, Vierucci A. Milk allergy/intolerance and atopic dermatitis in infancy and childhood. Allergy 2001;56(suppl 67):105-108.
[PubMed]
18.
Host A, Halken S, Muraro A, et al: Dietary prevention of allergic diseases in infants and small children. Pediatr Allergy Immunol 2008;19:1-4.
[PubMed]
19.
World Health Organization: Infant and Young Child Nutrition: Global Strategy on Infant and Young Child Feeding. Report by the Secretariat. Fifty-Fifth World Health Assembly, 2002.
20.
Jin YY, Cao RM, Chen J, et al: Partially hydrolyzed cow's milk formula has a therapeutic effect on the infants with mild to moderate atopic dermatitis: a randomized, double-blind study. Pediatr Allergy Immunol 2011;22:688-694.
[PubMed]
21.
Alexander DD, Cabana MD: Partially hydrolyzed 100% whey protein infant formula and reduced risk of atopic dermatitis: a meta-analysis. J Pediatr Gastroenterol Nutr 2010;50:422-430.
[PubMed]
22.
Hays T, Wood RA: A systematic review of the role of hydrolyzed infant formulas in allergy prevention. Arch Pediatr Adolesc Med 2005;159:810-816.
[PubMed]
23.
von Berg A, Filipiak-Pittroff B, Kramer U, et al: Preventive effect of hydrolyzed infant formulas persists until age 6 years: long-term results from the German Infant Nutritional Intervention Study (GINI). J Allergy Clin Immunol 2008;121:1442-1447.
[PubMed]
24.
Alexander DD, Schmitt DF, Tran NL, Barraj LM, Cushing CA: Partially hydrolyzed 100% whey protein infant formula and atopic dermatitis risk reduction: a systematic review of the literature. Nutr Rev 2010;68:232-245.
[PubMed]
25.
Greer FR, Sicherer SH, Burks AW; Committee on Nutrition and Section on Allergy and Immunology: Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics 2008;121:183-191.
[PubMed]
26.
Host A, Koletzko B, Dreborg S, et al: Dietary products used in infants for treatment and prevention of food allergy. Joint Statement of the European Society for Paediatric Allergology and Clinical Immunology (ESPACI) Committee on Hypoallergenic Formulas and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition. Arch Dis Child 1999;81:80-84.
[PubMed]
27.
Iskedjian M, Dupont C, Spieldenner J, et al: Economic evaluation of a 100% whey-based, partially hydrolysed formula in the prevention of atopic dermatitis among French children. Curr Med Res Opin 2010;26:2607-2626.
[PubMed]
28.
Spieldenner J, Belli D, Dupont C, et al: Partially hydrolysed 100% whey-based infant formula and the prevention of atopic dermatitis: comparative pharmacoeconomic analyses. Ann Nutr Metab 2011;59(suppl 1):44-52.
[PubMed]
29.
Su J, Prescott S, Sinn J, et al: Cost-effectiveness of partially-hydrolyzed formula for prevention of atopic dermatitis in Australia. J Med Econ 2012;15:1064-1077.
[PubMed]
30.
Mertens J, Stock S, Lungen M, et al: Is prevention of atopic eczema with hydrolyzed formulas cost-effective? A health economic evaluation from Germany. Pediatr Allergy Immunol 2012;23:597-604.
[PubMed]
31.
Bhanegaonkar AJ, Horodniceanu EG, Gonzalez RRH, et al: Cost-effectiveness of partially hydrolyzed whey protein formula in the primary prevention of atopic dermatitis in at-risk urban Filipino infants. Value Health Regional Issue 2014;3:124-135.
32.
Bhanegaonkar AJ, Lee BW, Shek Pei Chi L, et al: Modeling the cost-effectiveness of 100% whey-based partially hydrolyzed versus cow's milk infant formula in the prevention of atopic dermatitis in Singapore. Value Health 2014;17:A779.
33.
Bhanegaonkar AJ, Horodniceanu EG, Latiff, et al: Cost-effectiveness of partially hydrolyzed whey protein formula in the primary prevention of atopic dermatitis in at-risk urban infants in Malaysia. Asia Pac Allergy, in press.
34.
Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-338.
[PubMed]
35.
von Berg A, Filipiak-Pittroff B, Kramer U, et al: Allergies in high-risk schoolchildren after early intervention with cow's milk protein hydrolysates: 10-year results from the German Infant Nutritional Intervention (GINI) study. J Allergy Clin Immunol 2013;131:1565-1573.
[PubMed]
36.
Pitt M, Garside R, Stein K: A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 2006;154:1137-1146.
[PubMed]
37.
Stevens KJ, Brazier JE, McKenna SP, Doward LC, Cork MJ: The development of a preference-based measure of health in children with atopic dermatitis. Br J Dermatol 2005;153:372-377.
[PubMed]
You do not currently have access to this content.